ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Everolimus in Liver Transplantation for Diffuse, Unresectable Neuroendocrine Tumor

J. M. Vanatta1, R. A. Helmick2, C. Eymard2, N. Nezakatgoo2, P. Horton2, J. P. Kothadia2, S. P. Nair2, J. D. Eason2

1Transplantation, University of Tennessee/Methodist University Hospital, Memphis, TN, 2Transplantation, University of Tennessee, Memphis, TN

Meeting: 2022 American Transplant Congress

Abstract number: 1098

Keywords: Immunosuppression, Malignancy, Tumor recurrence

Topic: Clinical Science » Liver » 56 - Liver: Hepatocellular Carcinoma and Other Malignancies

Session Information

Session Name: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Liver transplantation (LT) has emerged as a therapy in selected patients for neuroendocrine tumor (NET) by providing cytoreduction. Progression-free survival in NET has been increased by everolimus (EVR), a mTOR inhibitor used to prevent rejection in transplantation. The purpose is to report experience with EVR for immuosuppression and antitumor effects in LT for NET.

*Methods: This is a retrospective study of LT for NET and immunosuppression management. Induction with steroid-free rabbit anti-thymocyte globulin was followed by primary immunosuppression with tacrolimus (TAC) prior to or EVR from December 2010. Characteristics, recurrence free-survival (RFS), and overall survival (OS) were compared between the two groups.

*Results: Twenty-two recipients of LT for NET were treated at our center with 12 EVR and 8 TAC as primary immunosuppression. Two patients died prior to initiating immunosuppression. Group features are compared in Table 1. Twelve (50%) developed recurrent NET–5/10 EVR group and 7/8 TAC group. The 1-, 3-, and 5-year RFS were 80%, 80%, and 69% in EVR group and 66%, 38%, and 19% in TAC group, respectively (p=0.034). Patient OS at 1-, 3-, and 5-year were 91%, 82%, and 72% in EVR group and 100%, 87.5%, and 50% in TAC group, respectively (p=0.707). EVR as immunosuppression and primary tumor high KI67 were significant variables in univariate analysis and only EVR as immunosuppression was significant in multivariate analysis for RFS with no significant variable for OS. These analyses for RFS are presented in Table 2.

*Conclusions: This study suggests that EVR is acceptable as both primary immunosuppression and adjuvant anti-tumor therapy for LT in NET patients. There may be an improvement in RFS compared to TAC as seen in this small sample. Multicenter, randomized controlled trials should be considered.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Vanatta JM, Helmick RA, Eymard C, Nezakatgoo N, Horton P, Kothadia JP, Nair SP, Eason JD. Everolimus in Liver Transplantation for Diffuse, Unresectable Neuroendocrine Tumor [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/everolimus-in-liver-transplantation-for-diffuse-unresectable-neuroendocrine-tumor/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences